Solid Tumors — Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
Citation(s)
An Open-Label, Clinical Trial Evaluating the Safety and Pharmacokinetics of Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors